iTeos Therapeutics (ITOS) Stock Price, News & Analysis - MarketBeat

2 days ago · MarketBeat has tracked 7 news articles for iTeos Therapeutics this week, compared to 2 articles on an average week. Search Interest Only 1 people have searched for ITOS on …

9%
OFF

ITeos Therapeutics (ITOS) News Today - MarketBeat

1 week from now

Jan 3, 2025 · State Street Corp increased its stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 21.9% during the third quarter, according to its most recent filing with the …

marketbeat.com

$7.68
OFF

ITeos Therapeutics’ (ITOS) “Buy” Rating ... - ETF Daily News

1 week from now

Dec 16, 2024 · iTeos Therapeutics stock opened at $7.68 on Friday. The business’s 50-day moving average price is $8.74 and its 200 day moving average price is $12.92. The firm has a …

etfdailynews.com

$21.00
OFF

ITeos Therapeutics: Promising Phase 2 Data Boosts Buy Rating On …

1 week from now

1 day ago · H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on iTeos Therapeutics (ITOS – Research Report) today and set a price target of $21.00. Discover …

businessinsider.com

$1.05
OFF

ITeos Therapeutics' (ITOS) "Outperform" Rating Reaffirmed

1 week from now

6 days ago · iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($1.05) EPS for the …

marketbeat.com

88%
OFF

Head To Head Review: ITeos Therapeutics (NASDAQ:ITOS ... - ETF …

1 week from now

1 day ago · Invivyd presently has a consensus price target of $7.89, indicating a potential upside of 1,808.88%. iTeos Therapeutics has a consensus price target of $22.25, indicating a …

etfdailynews.com

$7.26
OFF

ITeos Therapeutics (NASDAQ:ITOS) Price Target Lowered To

1 week from now

Dec 19, 2024 · Check Out Our Latest Analysis on ITOS iTeos Therapeutics Stock Performance. ITOS remained flat at $7.26 during trading on Thursday. 20,387 shares of the company were …

marketbeat.com

$1.05
OFF

ITeos Therapeutics (ITOS) Earnings Date And Reports 2025

1 week from now

iTeos Therapeutics posted Q3 2024 earnings on November 12, 2024, reporting an EPS of -$1.05, which topped the consensus estimate of -$1.18 by $0.13. With a trailing EPS of -$3.15, iTeos …

marketbeat.com

FAQs about iTeos Therapeutics (ITOS) Stock Price, News & Analysis - MarketBeat Coupon?

How much does ITOS iTeos Therapeutics (ITOS) stock cost?

ITOS iTeos Therapeutics, Inc. Stock Price & Overview Follow $8.810.36(+4.26%)4:00 PM 11/01/24 NASDAQ |$USD |Post-Market:$8.815:53 PM Summary Ratings Financials Earnings Dividends Valuation Growth Profitability Momentum Peers Options Charting All Analysis Comments News Transcripts SEC Filings Press Releases Related Analysis ITOS Stock Price 1D 5D 1M ...

Does iTeos Therapeutics (ITOs) have a free account?

Register for your free account today at data.nasdaq.com. Discover real-time iTeos Therapeutics, Inc. Common Stock (ITOS) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Stay ahead with Nasdaq. ...

How much is iTeos Therapeutics stock now?

iTeos Therapeutics' stock was trading at $10.95 at the start of the year. Since then, ITOS stock has decreased by 33.2% and is now trading at $7.32. How were iTeos Therapeutics' earnings last quarter? iTeos Therapeutics, Inc. (NASDAQ:ITOS) issued its quarterly earnings results on Tuesday, November, 12th. ...

Where is iTeos Therapeutics headquartered?

Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts. Read More… iTeos Therapeutics scored higher than 73% of companies evaluated by MarketBeat, and ranked 311th out of 948 stocks in the medical sector. ...

What is Wells Fargo's price target for iTeos Therapeutics (ITOS)?

Wells Fargo lowered the firm’s price target on iTeos Therapeutics (ITOS) to $19 from $31 and keeps an Overweight rating on the shares. The firm adjusted price targets in the Smid-cap biotechnology group as part of its 2025 outlook. ...

How much EPS does iTeos therapeutics have?

The company reported ($1.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.18) by $0.13. Sell-side analysts anticipate that iTeos Therapeutics will post -3.46 EPS for the current fiscal year. In other news, CFO Matthew Gall acquired 5,000 shares of the stock in a transaction dated Tuesday, November 19th. ...